Findings

What do systematic reviews say?

61 questions · 67 findings · 11 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 3%GRADE not reported 0 · 0%Very low 14 · 20.9%Low 29 · 43.3%Moderate 20 · 29.9%High 2 · 3%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Buprenorphine vs clonidine · Duration and severity of signs and symptoms of withdrawal Adjective rating scale
  Detoxification treatments for opiate dependent adolescents 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Moderate
Direct match · question page
- Buprenorphine vs clonidine · Drop out Number of participants who did not complete the detoxification treatment
  Detoxification treatments for opiate dependent adolescents 2014 · Cochrane Headline outcomes only
  RR 0.45 [0.2, 1.04]
  1 study · 36 participants
  Moderate
Direct match · question page
- Buprenorphine vs methadone · Completion of withdrawal treatment
  Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
  RR 1.04 [0.91, 1.2]
  5 studies · 457 participants
  Moderate
Direct match · question page
- Community‐based buprenorphine vs placebo · End of treatment drug use
  Interventions for female drug‐using offenders 2019 · Cochrane Headline outcomes only
  RR 0.57 [0.27, 1.2]
  1 study · 36 participants
  Very low
Direct match · question page
- Buprenorphine detox vs buprenorphine maintenance · Self‐reported use at 12 months
  Detoxification treatments for opiate dependent adolescents 2014 · Cochrane Headline outcomes only
  RR 1.36 [1.05, 1.76]
  1 study · 152 participants
  Low

Buprenorphine vs methadone

Mean days in treatment · Adults with opioid dependence

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 82 participants
Low

Buprenorphine vs methadone

Number completing withdrawal treatment · Adults with opioid dependence

Buprenorphine showed no clear difference in completion of withdrawal treatment compared with methadone (moderate certainty).

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
RR 1.04 [0.91, 1.2]
5 studies · 457 participants
Moderate

Buprenorphine vs alpha2‐adrenergic agonists

Peak withdrawal score · Adults or adolescents with opioid dependence

It is very uncertain whether buprenorphine changes mean peak withdrawal score, compared with alpha2‐adrenergic agonists (very low certainty).

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 521 participants
Very low

Buprenorphine vs alpha2‐adrenergic agonists

Mean overall withdrawal score (participant rated) · Adults or adolescents with opioid dependence

Buprenorphine showed no clear difference in mean overall withdrawal score, with various methods of assessment compared with alpha2‐adrenergic agonists (moderate certainty).

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 902 participants
Moderate

Buprenorphine vs alpha2‐adrenergic agonists

Mean days in treatment (with varying scheduled duration) · Adults or adolescents with opioid dependence

Buprenorphine probably leads to higher mean days in treatment (with varying scheduled duration) compared with alpha2‐adrenergic agonists (moderate certainty).

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
SMD 0.92 [0.57, 1.27]
4 studies · 558 participants
Moderate

Buprenorphine vs alpha2‐adrenergic agonists

Number experiencing adverse effects · Adults or adolescents with opioid dependence

It is very uncertain whether buprenorphine changes number experiencing adverse effects compared with alpha2‐adrenergic agonists (very low certainty).

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
RR 0.93 [0.7, 1.26]
3 studies · 493 participants
Very low

Buprenorphine vs alpha2‐adrenergic agonists

Number with treatment stopped due to adverse effects · Adults or adolescents with opioid dependence

Buprenorphine showed no clear difference in number with treatment stopped due to adverse effects compared with alpha2‐adrenergic agonists (low certainty).

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
RR 0.2 [0.04, 1.15]
3 studies · 134 participants
Low

Buprenorphine vs alpha2‐adrenergic agonists

Number completing withdrawal treatment · Adults or adolescents with opioid dependence

Buprenorphine probably leads to higher number completing withdrawal treatment compared with alpha2‐adrenergic agonists (moderate certainty).

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
RR 1.59 [1.23, 2.06]
11 studies · 1264 participants
Moderate

Buprenorphine detox vs buprenorphine maintenance

Total number of drop‐outs · patients with opiate dependent adolescents

Buprenorphine detox may leads to higher drop out Number of participants who dropped out from the study compared with buprenorphine maintenance (low certainty).

1 finding from 1 review

Detoxification treatments for opiate dependent adolescents 2014 · Cochrane Headline outcomes only
RR 2.67 [1.85, 3.86]
1 study · 152 participants
Low

Buprenorphine detox vs buprenorphine maintenance

Patients with positive urine at the end of treatment Number of participants with urine positive for opiates · patients with opiate dependent adolescents

Buprenorphine detox showed no clear difference in patients with positive urine at the end of treatment Number of… compared with buprenorphine maintenance (low certainty).

1 finding from 1 review

Detoxification treatments for opiate dependent adolescents 2014 · Cochrane Headline outcomes only
RR 1.03 [0.82, 1.28]
1 study · 152 participants
Low

Buprenorphine detox vs buprenorphine maintenance

Self‐reported use at 12 months · patients with opiate dependent adolescents

Buprenorphine detox may leads to higher self‐reported use at 12 months compared with buprenorphine maintenance (low certainty).

1 finding from 1 review

Detoxification treatments for opiate dependent adolescents 2014 · Cochrane Headline outcomes only
RR 1.36 [1.05, 1.76]
1 study · 152 participants
Low

Buprenorphine detox vs buprenorphine maintenance

Enrolment in addiction treatment at 12 month · patients with opiate dependent adolescents

Buprenorphine detox showed no clear difference in enrolment in addiction treatment at 12 month compared with buprenorphine maintenance (low certainty).

1 finding from 1 review

Detoxification treatments for opiate dependent adolescents 2014 · Cochrane Headline outcomes only
RR 0.75 [0.53, 1.07]
1 study · 152 participants
Low

Buprenorphine vs clonidine

Drop‐out (end of treatment) · patients with opiate dependent adolescents

Buprenorphine showed no clear difference in drop out Number of participants who did not complete the… compared with clonidine (moderate certainty).

1 finding from 1 review

Detoxification treatments for opiate dependent adolescents 2014 · Cochrane Headline outcomes only
RR 0.45 [0.2, 1.04]
1 study · 36 participants
Moderate

Buprenorphine vs clonidine

Withdrawal symptoms · patients with opiate dependent adolescents

1 finding from 1 review

Detoxification treatments for opiate dependent adolescents 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Moderate

Buprenorphine vs clonidine

Initiation of naltrexone treatment Number of participants initiating naltrexone · patients with opiate dependent adolescents

Buprenorphine probably leads to higher initiation of naltrexone treatment Number of participants initiating… compared with clonidine (moderate certainty).

1 finding from 1 review

Detoxification treatments for opiate dependent adolescents 2014 · Cochrane Headline outcomes only
RR 11 [1.58, 76.55]
1 study · 36 participants
Moderate

Buprenorphine maintenance vs buprenorphine detoxification

Total number of drop‐outs

Buprenorphine maintenance may leads to lower drop‐outs Number of participants who did not complete the study compared with buprenorphine detoxification (low certainty).

1 finding from 1 review

Maintenance treatments for opiate ‐dependent adolescents 2014 · Cochrane Headline outcomes only
RR 0.37 [0.26, 0.54]
1 study · 152 participants
Low

Buprenorphine maintenance vs buprenorphine detoxification

Use of Primary Substance

Buprenorphine maintenance showed no clear difference in use of primary substance Patients with positive urine test at the… compared with buprenorphine detoxification (low certainty).

1 finding from 1 review

Maintenance treatments for opiate ‐dependent adolescents 2014 · Cochrane Headline outcomes only
RR 0.97 [0.78, 1.22]
1 study · 152 participants
Low

Buprenorphine maintenance vs buprenorphine detoxification

Self reported use at 12‐month

Buprenorphine maintenance may leads to lower self reported use at 12‐month compared with buprenorphine detoxification (low certainty).

1 finding from 1 review

Maintenance treatments for opiate ‐dependent adolescents 2014 · Cochrane Headline outcomes only
RR 0.73 [0.57, 0.95]
1 study · 152 participants
Low

Buprenorphine maintenance vs buprenorphine detoxification

Enrolment in addiction treatment at 12 month

Buprenorphine maintenance showed no clear difference in enrolment in addiction treatment at 12‐month compared with buprenorphine detoxification (low certainty).

1 finding from 1 review

Maintenance treatments for opiate ‐dependent adolescents 2014 · Cochrane Headline outcomes only
RR 1.33 [0.94, 1.88]
1 study · 152 participants
Low

Community‐based buprenorphine vs placebo

Drug use · female offenders

It is very uncertain whether community‐based buprenorphine changes end of treatment drug use compared with placebo (very low certainty).

2 findings from 1 review

Interventions for female drug‐using offenders 2019 · Cochrane Headline outcomes only
RR 0.57 [0.27, 1.2]
1 study · 36 participants
Very low
Interventions for female drug‐using offenders 2019 · Cochrane Headline outcomes only
RR 0.58 [0.25, 1.35]
1 study · 36 participants
Very low